Alkermes PLC (ALKS) Director Paul J. Mitchell Sells 1,500 Shares

Alkermes PLC (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,500 shares of Alkermes PLC stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $54.91, for a total value of $82,365.00. Following the sale, the director now owns 9,500 shares in the company, valued at $521,645. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of Alkermes PLC (NASDAQ:ALKS) traded down 0.04% during mid-day trading on Friday, hitting $50.90. The stock had a trading volume of 701,043 shares. The stock’s market cap is $7.82 billion. Alkermes PLC has a 12-month low of $41.93 and a 12-month high of $63.40. The firm’s 50-day moving average price is $55.78 and its 200 day moving average price is $57.15.

Alkermes PLC (NASDAQ:ALKS) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.01 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The firm had revenue of $218.80 million for the quarter, compared to analyst estimates of $216.54 million. During the same period last year, the company earned ($0.01) EPS. The business’s quarterly revenue was up 12.1% compared to the same quarter last year. Equities analysts forecast that Alkermes PLC will post ($0.04) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Rincon Hill News and is owned by of Rincon Hill News. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://rinconhillneighbors.org/2017/08/19/insider-selling-alkermes-plc-alks-director-sells-1500-shares-of-stock-updated-updated.html.

Several hedge funds and other institutional investors have recently bought and sold shares of ALKS. Russell Investments Group Ltd. bought a new position in Alkermes PLC during the fourth quarter valued at about $439,000. Dimensional Fund Advisors LP raised its position in Alkermes PLC by 4.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 191,640 shares of the company’s stock valued at $10,651,000 after buying an additional 7,797 shares in the last quarter. Creative Planning raised its position in Alkermes PLC by 16.2% in the first quarter. Creative Planning now owns 18,012 shares of the company’s stock valued at $1,054,000 after buying an additional 2,510 shares in the last quarter. Capstone Asset Management Co. raised its position in Alkermes PLC by 8.0% in the first quarter. Capstone Asset Management Co. now owns 6,585 shares of the company’s stock valued at $385,000 after buying an additional 490 shares in the last quarter. Finally, Parametrica Management Ltd bought a new position in Alkermes PLC during the first quarter valued at about $518,000. Institutional investors and hedge funds own 97.19% of the company’s stock.

Several equities research analysts have issued reports on the company. J P Morgan Chase & Co set a $78.00 price objective on Alkermes PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. ValuEngine upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Morgan Stanley reiterated an “equal weight” rating and issued a $62.00 price target on shares of Alkermes PLC in a report on Monday, April 24th. Leerink Swann downgraded Alkermes PLC from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $68.00 to $61.00 in a report on Tuesday, June 13th. Finally, BidaskClub downgraded Alkermes PLC from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. Alkermes PLC has an average rating of “Hold” and a consensus price target of $63.00.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.